Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI Doctor's helper: could a smart system improve heart and diabetes care?

NCT ID NCT07350486

Disease control Sponsor: First Hospital of China Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 04, 2026 · Updated 1 time

Summary

This study will test whether an artificial intelligence (AI) system can help community doctors better manage patients who have high blood pressure along with diabetes or high cholesterol. About 6,800 adults will be split into two groups: one where doctors use the AI tool to guide treatment and follow-up, and another where they receive usual care. The goal is to see if the AI approach helps more patients reach healthy targets for blood pressure, blood sugar, and cholesterol.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Large language model (AI) software that helps community doctors coordinate care for multiple conditions
What this could lead to
If it works, this could show that AI-assisted community care improves control of blood pressure, blood sugar, and cholesterol in people with multiple conditions.
What could go wrong
This trial has not started yet and is testing a new AI system, so results are uncertain. The AI may not work as well in real-world community settings or may have technical issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 6,800 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Participating communities must meet all of the following criteria: * Have a designated community physician responsible for primary care who is capable of using a smartphone with stable internet access for clinical communication and LLM-assisted management; * No plan for administrative merger or restructuring within the next three years; * Located at least 2 kilometers away from adjacent participating communities (to minimize contamination between clusters). Eligible participants must fulfill all of the following conditions: * Aged 40 years or older; * Uncontrolled hypertension, defined as systolic blood pressure (SBP) ≥140 mmHg or diastolic blood pressure (DBP) ≥ 90 mmHg; * Coexisting diabetes (HbA1c ≥ 7.0%) or coexisting dyslipidemia (LDL-C ≥ 3.4 mmol/L\[130 mg/dL\]); * Able to use a smartphone independently or with assistance from family members; * Has resided in the participating community for at least 6 months; * Has no plan to relocate in the next 3 years; * Enrolled in basic medical insurance for urban and rural residents, employee medical insurance, or the New Rural Cooperative Medical Scheme; * Not currently pregnant or planning pregnancy during the study period; * Free from malignant tumors and deemed to have a life expectancy of at least 3 years, as judged by study physicians; * Willing and able to provide written informed consent. Exclusion Criteria:No specific exclusion criteria.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetes mellitus Dyslipidemias hypertensive disorder inherited lipid metabolism disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes Dyslipidemia Hypertension

Contacts and locations

Locations

  • Binhai New Area

    Tianjin, China

  • Cangzhou

    Cangzhou, Hebei, China

  • Dawa District

    Panjin, Liaoning, China

  • Shenyang

    Shenyang, Liaoning, China

  • Wujiang District

    Suzhou, Jiangsu, China

  • Yiwu

    Jinzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.